The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 26, 2026

Filed:

Oct. 10, 2019
Applicants:

University of Padova, Padua, IT;

Mggm Llc, New York, NY (US);

Institute for Research IN Biomedicine, Bellinzona, CH;

Inventors:

Paolo L. Manfredi, Miami Beach, FL (US);

Charles E. Inturrisi, New York, NY (US);

Andrea Mattarei, Perarolo di Vigonza, IT;

Sara De Martin, Vigonza, IT;

Jacopo Sgrignani, Almenno San Salvatore, IT;

Andrea Cavalli, Zurich, CH;

Assignees:

MGGM LLC, Kerhonkson, NY (US);

University of Padova, Padua, IT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 225/16 (2006.01); C07C 225/18 (2006.01); C07C 229/34 (2006.01); C07C 323/29 (2006.01); C07D 207/09 (2006.01); C07D 209/14 (2006.01); C07D 233/64 (2006.01); C07D 295/135 (2006.01); C07D 317/58 (2006.01); C07D 319/06 (2006.01); C07D 333/28 (2006.01);
U.S. Cl.
CPC ...
C07C 225/16 (2013.01); C07C 225/18 (2013.01); C07C 229/34 (2013.01); C07C 323/29 (2013.01); C07D 207/09 (2013.01); C07D 209/14 (2013.01); C07D 233/64 (2013.01); C07D 295/135 (2013.01); C07D 317/58 (2013.01); C07D 319/06 (2013.01); C07D 333/28 (2013.01); C07B 2200/05 (2013.01);
Abstract

Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The structural modifications of an opioid or opioid enantiomer that result in the SMOs can be obtained by starting the synthetic process de novo; by modifying the synthetic process for the opioid at any intermediate step during the synthesis of the racemate or of one enantiomer; or by modifying the structure of the opioid or opioid enantiomer after the synthesis. The nitric acid ester substitutions are of particular relevance, especially when associated to deuterated substitutions and/or halogen substitutions.


Find Patent Forward Citations

Loading…